KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD

American Journal of Kidney Diseases

Volumn 52, Issue 5, 2008, Pages 811-825

  Gordon, Craig E ^a   Balk, Ethan M ^a   Becker, Bryan N ^b   Crooks, Peter A ^c   Jaber, Bertrand L ^d   Johnson, Cynda A ^e   Michael, Maureen A ^f   Pereira, Brian J G ^g   Uhlig, Katrin ^a   Levin, Adeera ^h  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c KAISER PERMANENTE   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^f Central Florida Kidney Centers Inc   (United States)

^g AMAG PHARMACEUTICALS INC   (United States)

^h ST PAUL S HOSPITAL   (Canada)

Author keywords

chronic kidney disease; guideline; hemodialysis; Hepatitis C; hepatitis C virus (HCV); Kidney Disease Outcomes Quality Initiative (KDOQI); Kidney Disease: Improving Global Outcomes (KDIGO); transplant

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; STEROID;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CRYOGLOBULINEMIA; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; FLU LIKE SYNDROME; FOCAL GLOMERULOSCLEROSIS; GRAFT FAILURE; GRAFT REJECTION; HEADACHE; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CIRRHOSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONOTHERAPY; PRACTICE GUIDELINE; PREVALENCE;

EID: 54149114155     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.08.005     Document Type: Note

References (71)

1. Eknoyan G., Lameire N., Barsoum R., et al. The burden of kidney disease: Improving global outcomes. Kidney Int 66 (2004) 1310-1314
2. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 109 (2008) S1-S99
3. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
4. Dalrymple L.S., Koepsell T., Sampson J., et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2 (2007) 715-721
5. Tsui J.I., Vittinghoff E., Shlipak M.G., and O'Hare A.M. Relationship between hepatitis C and chronic kidney disease: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 17 (2006) 1168-1174
6. Tsui J.I., Vittinghoff E., Shlipak M.G., et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 167 (2007) 1271-1276
7. Fabrizi F., Martin P., Dixit V., Bunnapradist S., and Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20 (2004) 1271-1277
8. Fabrizi F., Martin P., Dixit V., Bunnapradist S., and Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 5 (2005) 1452-1461
9. Uhlig K., Macleod A., Craig J., et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70 (2006) 2058-2065
10. Fervers B., Burgers J.S., Haugh M.C., et al. Adaptation of clinical guidelines: Literature review and proposition for a framework and procedure. Int J Qual Health Care 18 (2006) 167-176
11. Schunemann H.J., Fretheim A., and Oxman A.D. Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation. Health research policy and systems. Health Res Policy Syst 4 (2006) 25
12. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
13. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130 (2006) 231-264 quiz, 214-237
14. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 123 (2002) 2082-2099
15. Tokars J.I., Arduino M.J., and Alter M.J. Infection control in hemodialysis units. Infect Dis Clin North Am 15 (2001) 797-812 viii
16. Alter M.J., Kuhnert W.L., Finelli L., and Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep 52 (2003) 1-13 15; quiz, CE11-CE14
17. Soma J., Saito T., Taguma Y., et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 11 (2000) 690-699
18. Stehman-Breen C., Willson R., Alpers C.E., Gretch D., and Johnson R.J. Hepatitis C virus-associated glomerulonephritis. Curr Opin Nephrol Hypertens 4 (1995) 287-294
19. Fissell R.B., Bragg-Gresham J.L., Woods J.D., et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 65 (2004) 2335-2342
20. dos Santos J.P., Loureiro A., Cendoroglo Neto M., and Pereira B.J. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 11 (1996) 2017-2022
21. Bruno S., Battezzati P.M., Bellati G., et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 34 (2001) 748-755
22. Yoshida H., Arakawa Y., Sata M., et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123 (2002) 483-491
23. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997) 875-881
24. Reichard O., Glaumann H., Fryden A., Norkrans G., Wejstal R., and Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 30 (1999) 783-787
25. Yoshida H., Shiratori Y., Moriyama M., et al., IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
26. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
27. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358 (2001) 958-965
28. Hoffmann-La Roche Inc. Peginterferon alfa-2a [package insert] (2002), Hoffmann-La Roche Inc, Nutley, NJ
29. Schering Corp. Peginterferon alfa-2b [package insert] (2001), Schering Corp, Kenilworth, NJ
30. Schering Corp. Ribavirin [package insert] (2003), Schering Corp, Kenilworth, NJ
31. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., and Martin P. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18 (2003) 1071-1081
32. Russo M.W., Goldsweig C.D., Jacobson I.M., and Brown Jr. R.S. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 98 (2003) 1610-1615
33. Kokoglu O.F., Ucmak H., Hosoglu S., et al. Efficacy and tolerability of pegylated interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21 (2006) 575-580
34. Russo M.W., Ghalib R., Sigal S., and Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21 (2006) 437-443
35. Sporea I., Popescu A., Sirli R., et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 12 (2006) 4191-4194
36. Rostaing L., Izopet J., Baron E., Duffaut M., Puel J., and Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59 (1995) 1426-1431
37. Rostaing L., Modesto A., Baron E., Cisterne J.M., Chabannier M.H., and Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74 (1996) 512-516
38. Kamar N., Sandres-Saune K., Selves J., et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis 42 (2003) 184-192
39. Mandal A.K., Kraus E.S., Samaniego M., et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transpl 14 (2000) 391-396
40. Castell J., and Gutierrez G. [Outbreak of 18 cases of hepatitis C in a hemodialysis unit]. Gaceta Sanitaria/SESPA 19 (2005) 214-220
41. Kondili L.A., Genovese D., Argentini C., et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis 25 (2006) 527-531
42. Savey A., Simon F., Izopet J., Lepoutre A., Fabry J., and Desenclos J.C. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol 26 (2005) 752-760
43. Le Pogam S., Le Chapois D., Christen R., Dubois F., Barin F., and Goudeau A. Hepatitis C in a hemodialysis unit: Molecular evidence for nosocomial transmission. J Clin Microbiol 36 (1998) 3040-3043
44. Thompson NBS: Hepatitis C Virus Transmission in the Hemodialysis Setting: Importance of Infection Control Practices and Aseptic Technique. Poster presented at: National Kidney Foundation 2008 Spring Clinical Meeting, Dallas, Texas, April 2-6, 2008
45. Jadoul M., Cornu C., van Ypersele de Strihou C., and The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian Multicenter Study. Kidney Int 53 (1998) 1022-1025
46. Petrosillo N., Gilli P., Serraino D., et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 37 (2001) 1004-1010
47. Finelli L., Miller J.T., Tokars J.I., Alter M.J., and Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18 (2005) 52-61
48. Jadoul M., Cornu C., van Ypersele de Strihou C., and The UCL Collaborative Group. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int 44 (1993) 1322-1326
49. Bloom R.D., Sayer G., Fa K., Constantinescu S., Abt P., and Reddy K.R. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 5 (2005) 139-144
50. Knoll G.A., Tankersley M.R., Lee J.Y., Julian B.A., and Curtis J.J. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 29 (1997) 608-614
51. Pereira B.J., Natov S.N., Bouthot B.A., et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 53 (1998) 1374-1381
52. Abbott K.C., Bucci J.R., Matsumoto C.S., et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 14 (2003) 2908-2918
53. Meier-Kriesche H.U., Ojo A.O., Hanson J.A., and Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 72 (2001) 241-244
54. Pereira B.J. Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 10 suppl 1 (1995) S58-S67
55. Bruchfeld A., Wilczek H., and Elinder C.G. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78 (2004) 745-750
56. Morales J.M., Dominguez-Gil B., Sanz-Guajardo D., Fernandez J., and Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 19 suppl 3 (2004) Siii72-Siii76
57. Abbott K.C., Lentine K.L., Bucci J.R., et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 15 (2004) 3166-3174
58. Bloom R.D., Rao V., Weng F., Grossman R.A., Cohen D., and Mange K.C. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13 (2002) 1374-1380
59. Kasiske B.L., Snyder J.J., Gilbertson D., and Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 (2003) 178-185
60. Morales J.M., Pascual-Capdevila J., Campistol J.M., et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 63 (1997) 1634-1639
61. Roth D., Cirocco R., Zucker K., et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 59 (1995) 1676-1682
62. Kamar N., Toupance O., Buchler M., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14 (2003) 2092-2098
63. Campistol J.M., Esforzado N., Martinez J., et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 14 (1999) 2704-2709
64. Casanovas-Taltavull T., Baliellas C., Benasco C., et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: Results after transplantation. Am J Gastroenterol 96 (2001) 1170-1177
65. Cruzado J.M., Casanovas-Taltavull T., Torras J., Baliellas C., Gil-Vernet S., and Grinyo J.M. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3 (2003) 357-360
66. Abbott K.C., Lentine K.L., Bucci J.R., Agodoa L.Y., Peters T.G., and Schnitzler M.A. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 4 (2004) 2032-2037
67. Natov S.N., Lau J.Y., Ruthazer R., Schmid C.H., Levey A.S., and Pereira B.J. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 56 (1999) 700-706
68. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11 suppl 15 (2000) S1-S86
69. Levey A.S., Atkins R., Coresh J., et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-A position statement from Kidney Disease: Improving Global Outcomes. Kidney Int 72 (2007) 247-259
70. Collins AJ K.B., Herzog C., et al. Excerpts from the United States Renal Data System 2007 Annual Data Report. Am J Kidney Dis 51 suppl 1 (2008) S1-S320
71. McHutchison J.G., Poynard T., Pianko S., et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119 (2000) 1317-1323